Business
Directorate change
SkinBioTherapeutics plc has announced directorate changes effective January 1, 2026, appointing Alyson Levett as a non-executive director and Chair of the Audit Committee, and promoting Emily Bertram to Chief Financial Officer and an executive director. Danielle Bekker has stepped down from the Board but will remain as an external advisor. Alyson Levett brings over 20 years of C-suite financial experience and expertise with AIM companies, while Emily Bertram is a qualified Chartered Accountant with extensive experience in finance roles across various industries. These appointments are intended to strengthen the Board's financial expertise and support executive management. Disclaimer*
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\n \nDirectorate Changes\n \n5 January 2026 - SkinBioTherapeutics, (AIM: SBTX), a life science company focused on skin health, announces the appointment of Alyson Levett as new non-executive director and Chair of the Audit Committee and the promotion of Emily Bertram to Chief Financial Officer and also to the Board. Danielle Bekker has stepped down from the Board but will continue to support as an external advisor effective from 31 December 2025. The appointments came into effect from 1 January 2026.\n \nAlyson Levett, Non-Executive Director and Chair of Audit Committee\nAlyson Levett is a highly experienced non-executive Director and Chair of Audit & Risk Committees. She has worked in a broad range of sectors including FMCG, food manufacturing, engineering and technology, with proven expertise with AIM companies and a wealth of shareholder and other stakeholder engagement and relationship experience. She has over 20 years C suite financial experience, culminating in being CFO at the strategy software company, i-nexus where she stayed for a decade taking it onto AIM in a successful IPO in 2018. She left to develop a portfolio Non-Executive career, focussing on the role of Chair of the Audit Committee or Audit & Risk Committee. Her current directorships are listed below, but include GETECH Group plc, Eleco plc and the Financial Services Compensation Scheme. She also acts as a Trustee on the charitable trust, En-Fold Autism Support, and is a volunteer advisor at The Cranfield Trust. She read Economics at Cambridge University and is a qualified Chartered accountant (ICAEW).\n \nEmily Bertram, Chief Financial Officer and Executive Officer to the Board\nEmily Bertram has been promoted from Group Finance Director to Chief Financial Officer and has become an executive Director on the Board of SkinBioTherapeutics, following the AGM. Emily is an experienced certified Chartered Accountant (ACCA) who has led and worked within finance teams in a variety of industries, from business advisory groups to medical technology and pharma companies, to banking. Before SkinBioTherapeutics, Emily was Group Head of Financial Planning and Analysis at Azets, the international business advisory group. Prior to this, she held senior fin...